"We are excited to launch DRAGEN v4.3, with significant enhancements and additions to our analysis tools, empowering researchers and geneticists to maximize the value of the genome," said Rami Mehio, head of Software & Informatics at Illumina. "DRAGEN v4.3 includes our next-generation and most accurate multigenome mapping technology, built-in mosaic calling, advancements in machine learning, and the ability to genotype difficult genes to unlock deeper insights into the human genome with greater power, accur ...

Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Illumina Inc (ILMN) - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering.This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. ...

INDIA - 2023/12/16: In this photo illustration, the Illumina logo is seen displayed on a mobile ... [+] phone screen. (Photo Illustration by Idrees Abbas/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesIllumina stock (NASDAQ: ILMN) saw a 7% rise on Thursday, June 6, faring better than its peer — Mettler-Toledo stock – down 1%. The rise in ILMN stock can primarily be attributed to the company’s decision to spin off its blood testing company – Grail. Illumina acquired Grail in ...

The New Jersey representative bought and sold some stock in April.On April 19, U.S. Rep. Thomas Kean Jr., R-N.J., bought shares of Illumina (ILMN -0.89%) and sold shares of Nike (NKE 0.87%), according to a May 31 filing. Although it's unclear exactly how many shares were involved in the trades, the amount reported for each transaction was between $1,001 and $15,000. From April 19 through the close of trading yesterday, Illumina stock had fallen 9.1%, and Nike stock was essentially flat, down less than 0.01% ...

"We are excited to deliver for our NextSeq 1000/2000 customers improved sequencing with faster run times, better quality, and higher output—all at lower cost per kit," said Jason Johnson, head of Global Product Management at Illumina. "XLEAP-SBS chemistry on NextSeq 1000/2000 will enable labs to perform bigger NGS projects without raising the budget, and facilitate greater adoption of multiomic approaches."In March, the company launched its P4 flow cell (highest output of 540 Gb) with XLEAP-SBS chemistry fo ...

Core Viewpoint - Illumina, Inc. has announced the spin-off of GRAIL, which is expected to be completed on June 24, 2024, marking a significant milestone for the company as it focuses on advancing genomics innovation and improving human health [1][2]. Stock Distribution - Illumina shareholders will receive one share of GRAIL common stock for every six shares of Illumina common stock held as of June 13, 2024, with a total distribution of 85.5% of GRAIL's outstanding common stock [2][3]. - Illumina will retain a 14.5% minority share in GRAIL following the spin-off [2]. Trading Details - "When-issued" trading for GRAIL common stock is expected to begin on or about June 12, 2024, under the ticker symbol "GRAL WI," transitioning to regular trading on June 25, 2024 [5]. - Illumina shares will trade in two markets: "regular way" with entitlement to GRAIL shares and "ex-distribution" without entitlement [5][6]. Fractional Shares - Fractional shares of GRAIL will not be distributed; instead, they will be aggregated and sold in the open market, with net proceeds distributed in cash to shareholders entitled to fractional shares [3]. Tax Implications - U.S. shareholders of Illumina generally will not recognize gain or loss from the distribution of GRAIL shares, except for cash received for fractional shares [4]. Company Information - Illumina is a leader in DNA sequencing and array-based technologies, focusing on improving human health through genomics [9]. - GRAIL aims to detect cancer early using advanced technologies, contributing to the fight against cancer [10].

Core Viewpoint - Illumina, Inc. has appointed Everett Cunningham as Chief Commercial Officer, effective June 10, 2024, to enhance its global commercial organization and drive growth in the healthcare sector [1][2]. Group 1: Appointment Details - Everett Cunningham will be responsible for building, guiding, and managing Illumina's global commercial organization [2]. - Cunningham has over 20 years of commercial leadership experience in healthcare technology, life sciences, and pharmaceuticals [1][2]. - He previously served as Chief Commercial Officer at Exact Sciences, overseeing marketing, sales, and customer service functions [2]. Group 2: Leadership Experience - Prior to his role at Exact Sciences, Cunningham held senior leadership positions at Quest Diagnostics, GE Healthcare, and Pfizer, where he spent 21 years [2]. - He has a proven track record in driving operational excellence, delivering top-line results, and expanding into new markets [2]. Group 3: Company Vision - Illumina's CEO, Jacob Thaysen, expressed enthusiasm for Cunningham's appointment, highlighting his experience and passion for addressing significant healthcare challenges [2]. - The company aims to leverage Cunningham's leadership to capitalize on its position in next-generation sequencing and meet customer needs [2].

Core Company Strategy - The primary focus for the company is to return to growth and drive operational excellence, with an emphasis on profitable growth moving forward [3][4] - The company is currently evaluating two scenarios regarding GRAIL: a potential spin-off or a sale, with the intention to reach a resolution by the end of June [5][6] Strategic Priorities - The company aims to articulate a comprehensive strategy in the latter part of the year, focusing on the genomics ecosystem and how to enhance its role within it [8][10] - The strategy will consider the evolution of sequencing technology and its applications, including multiomics and sample-to-answer workflows [9][10] Financial Outlook - The company plans to provide long-term guidance on revenue growth and profitability, aiming for a core operating margin of around 20% [12][13] - There is an expectation for a reduction in market-making investments as the market matures, potentially leading to improved profitability [22][23] Market Dynamics - The academic market is currently stable, with NIH funding showing slight growth, particularly in genomics-related areas [30][34] - The company is actively working to strengthen relationships with key opinion leaders (KOLs) and pharmaceutical partners to enhance its ecosystem and drive future growth [36][37] Clinical Market Insights - The clinical market is characterized by longer adoption cycles due to regulatory requirements, but there is potential for increased demand as new tests are developed [43][45] - The company believes that the elasticity of demand in clinical applications will evolve as new technologies are validated and adopted [42][45] Multiomics and Ecosystem Development - The company sees significant opportunities in multiomics and aims to integrate more workflows into its ecosystem, enhancing the overall scientific capabilities [55][56] - The focus is on improving efficiency and reducing manual processes in the workflow, rather than directly competing with existing partners [60][61] GRAIL Update - The company is on track to finalize decisions regarding GRAIL by the end of June, with both sale and spin-off scenarios being considered [62][63] - The execution timeline for either scenario is expected to be in months rather than years, with a focus on maintaining investment-grade status [66][69]

Core Insights - Illumina is presenting research at the ASCO Annual Meeting aimed at advancing genomic testing as a standard of care in oncology [2][3] - The studies focus on the clinical utility of comprehensive genomic profiling (CGP), overcoming market access barriers, and the development of molecular residual disease (MRD) assays [1][8] Group 1: Research Collaborations - Illumina and Labcorp have five abstracts accepted at ASCO, focusing on the clinical impact of comprehensive biomarker testing [3] - A notable study involves a machine learning algorithm for detecting tumor microsatellite instability (MSI) in colorectal cancer, analyzing samples from 1,838 patients [3][4] Group 2: Comprehensive Genomic Profiling (CGP) - Illumina is validating the clinical utility of CGP over single-gene testing (SGT), with a real-world analysis showing that only 1.2% of stage IV non-small-cell lung cancer (NSCLC) patients received results for all nine guideline-recommended biomarkers through SGT, compared to 71.7% for CGP [5][6] - This evidence supports the transition to comprehensive next-generation sequencing as the standard of care for NSCLC [6][7] Group 3: Molecular Residual Disease (MRD) Assay - Illumina will present an evaluation of its MRD assay, highlighting its fast turnaround time, low input requirements, and high sensitivity and specificity compared to existing market options [8] - Collaborations with pharmaceutical companies are underway to innovate on the MRD research assay, which is based on a whole-genome approach [8]

Core Insights - Illumina Inc. published its fifth annual Corporate Social Responsibility (CSR) Report, showcasing its commitments and progress in advancing human health in 2023 [1][2] Group 1: Accelerating Access to Genomics - Illumina is focused on making genomics accessible by reducing sequencing costs, entering new markets, and enhancing genomic data diversity [2] - In 2023, the company trained over 27,000 healthcare professionals and advocated for health care coverage for genomic testing, which increased from $1.2 billion to $1.3 billion [2] - New product launches included the NovaSeq™ X Series, TruSight™ Oncology 500 ctDNA v2 research assay, and the 25B flow cell, which can generate tens of thousands of whole genomes annually at the lowest cost per sample [2] Group 2: Nurturing People and Communities - Illumina maintained a zero net pay gap for the fifth consecutive year and achieved 45% female representation in its workforce, with a 5% increase in female leadership roles over the last three years [3] - Nearly 60% of employees participated in charitable giving and volunteering in 2023, reflecting the company's commitment to a purpose-driven culture [3] Group 3: Integrating Environmental Stewardship - The NovaSeq X Series uses more sustainable reagents, resulting in 90% less packaging weight and waste, 50% less plastic, and a 61% reduction in climate change impact [3] - For the second consecutive year, 100% of Illumina's global electricity consumption came from renewable sources [3] Group 4: Operating Responsibly - In 2023, Illumina ensured that 100% of its core facilities participated in third-party audit programs to strengthen ethical business practices [4] - The company expanded its ISO data privacy certification and completed the EU-US and Swiss-US Data Privacy Framework Self-Certification and ISO 27701 certification [4] - Illumina maintains strong corporate governance with an independent Board of Directors, an independent Board Chair, and 75% of standing committees chaired by women [4]